Vera Therapeutics (VERA) Gains from Sales and Divestitures (2021 - 2026)
Vera Therapeutics (VERA) reported Gains from Sales and Divestitures of $237070.0 for Q1 2026, up 171.57% on a YoY basis from $87296.0 in Q1 2025, and up 53.1% quarter-over-quarter from $154851.0 in Q4 2025.
Vera Therapeutics (VERA) Gains from Sales and Divestitures (2021 - 2026) Analysis & Trends
Vera Therapeutics has reported Gains from Sales and Divestitures for 6 years, with the latest figure at $237070.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Sales and Divestitures rose 171.57% year-over-year to $237070.0; the trailing twelve-month figure through Mar 2026 stood at $237070.0 (up 171.57% YoY), and the FY2025 full-year result was $154851.0, up 39.01% from the prior year.
- Gains from Sales and Divestitures for Q1 2026 stood at $237070.0, up from $154851.0 in the prior quarter.
- The five-year high for Gains from Sales and Divestitures was $237070.0 in Q1 2026, with the low at $938.0 in Q1 2024.
- Historically, Gains from Sales and Divestitures has averaged $77566.9 across 5 years, with a median of $72020.0 in 2022.
- Annual changes were most pronounced in 2023 — Gains from Sales and Divestitures sank 93.57% — and 2025, when it soared 9206.61%.
- Vera Therapeutics' Gains from Sales and Divestitures stood at $77719.0 in 2022, then retreated by 14.67% to $66321.0 in 2023, then surged by 67.96% to $111396.0 in 2024, then soared by 39.01% to $154851.0 in 2025, then soared by 53.1% to $237070.0 in 2026.
- The last three Gains from Sales and Divestitures figures came in at $237070.0 (Q1 2026), $154851.0 (Q4 2025), and $120031.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Vera Therapeutics | 2.45 Bn | 1.85 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 237,070.00 |
| Mar 31, 2026 | 237,070.00 |
| Dec 31, 2025 | 154,851.00 |
| Dec 31, 2025 | 154,851.00 |
| Sep 30, 2025 | 120,031.00 |
| Sep 30, 2025 | 120,031.00 |
| Jun 30, 2025 | 91,641.00 |
| Jun 30, 2025 | 91,641.00 |
| Mar 31, 2025 | 87,296.00 |
| Mar 31, 2025 | 87,296.00 |
| Dec 31, 2024 | 111,396.00 |
| Dec 31, 2024 | 111,396.00 |
| Sep 30, 2024 | 107,472.00 |
| Sep 30, 2024 | 107,472.00 |
| Jun 30, 2024 | 1,875.00 |
| Jun 30, 2024 | 1,875.00 |
| Mar 31, 2024 | 938.00 |
| Mar 31, 2024 | 938.00 |
| Dec 31, 2023 | 66,321.00 |
| Dec 31, 2023 | 66,321.00 |